Copiktra Side Effects Too Dangerous for Some Cancer Patients, FDA Advisory Committee Decides
An FDA advisory committee voted to recommend the agency not approve Copiktra for some blood cancer patients due to an increased risk of death.
An FDA advisory committee voted to recommend the agency not approve Copiktra for some blood cancer patients due to an increased risk of death.
An advisory committee is being asked to review the benefits and risks of Copiktra, a blood cancer drug FDA experts say appears to lower life expectancy in some cancer patients.
The FDA warns the cancer drug, Copiktra, may be linked to an increased risk of death among patients.